Published in FASEB J on March 29, 2006
Notch inhibits expression of the Krüppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol Cancer Res (2008) 1.46
Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther (2010) 1.45
Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy. Diabetes (2010) 1.21
Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvasc Res (2008) 1.08
Notch signaling in CD4 and CD8 T cell development. Curr Opin Immunol (2008) 1.06
Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. PLoS One (2010) 1.03
Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood (2011) 1.00
Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol (2008) 0.99
Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood (2008) 0.98
Endothelial differentiation: molecular mechanisms of specification and heterogeneity. Arterioscler Thromb Vasc Biol (2011) 0.98
Impact of notch signaling on inflammatory responses in cardiovascular disorders. Int J Mol Sci (2013) 0.96
Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Mol Cancer (2010) 0.91
Identification of E-selectin as a novel target for the regulation of postnatal neovascularization: implications for diabetic wound healing. Ann Surg (2010) 0.88
Flt-1 (vascular endothelial growth factor receptor-1) is essential for the vascular endothelial growth factor-Notch feedback loop during angiogenesis. Arterioscler Thromb Vasc Biol (2013) 0.88
Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther (2015) 0.88
Alcohol and cardiovascular disease--modulation of vascular cell function. Nutrients (2012) 0.87
Notch signalling in ischaemia-induced angiogenesis. Biochem Soc Trans (2009) 0.85
Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin. PLoS One (2009) 0.84
Gene expression profile in colon cancer cells with respect to XIAP expression status. Int J Colorectal Dis (2008) 0.84
Specification and function of hemogenic endothelium during embryogenesis. Cell Mol Life Sci (2016) 0.83
Inhibition of fibroblast growth by Notch1 signaling is mediated by induction of Wnt11-dependent WISP-1. PLoS One (2012) 0.83
Notch signaling in ocular vasculature development and diseases. Mol Med (2012) 0.82
Enhanced cellular responses and distinct gene profiles in human fetoplacental artery endothelial cells under chronic low oxygen. Biol Reprod (2013) 0.80
Regulation of non-classical FGF1 release and FGF-dependent cell transformation by CBF1-mediated notch signaling. J Cell Physiol (2011) 0.80
Endothelial sirtuin 1 inactivation enhances capillary rarefaction and fibrosis following kidney injury through Notch activation. Biochem Biophys Res Commun (2016) 0.77
Inflammation and Notch signaling: a crosstalk with opposite effects on tumorigenesis. Cell Death Dis (2016) 0.76
Jagged-1 Signaling in the Bone Marrow Microenvironment Promotes Endothelial Progenitor Cell Expansion and Commitment of CD133+ Human Cord Blood Cells for Postnatal Vasculogenesis. PLoS One (2016) 0.75
Long telomeres protect against age-dependent cardiac disease caused by NOTCH1 haploinsufficiency. J Clin Invest (2017) 0.75
Autophagy negatively regulates tumor cell proliferation through phosphorylation dependent degradation of the Notch1 intracellular domain. Oncotarget (2016) 0.75
Integrin β3/Akt signaling contributes to platelet-induced hemangioendothelioma growth. Sci Rep (2017) 0.75
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 4.12
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest (2007) 3.63
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol (2006) 2.85
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem (2002) 2.58
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
Is there still a glass ceiling for women in academic surgery? Ann Surg (2011) 2.33
Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim (2006) 2.32
Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 2.29
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood (2008) 2.24
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Idiopathic mid-aortic syndrome in children. Pediatr Nephrol (2008) 2.14
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Enhanced tumor formation in mice heterozygous for Blm mutation. Science (2002) 2.07
Treatment of type 2 endoleaks after endovascular repair of abdominal aortic aneurysms: comparison of transarterial and translumbar techniques. J Vasc Surg (2002) 2.05
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat Oncol Biol Phys (2013) 2.01
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development (2004) 1.91
Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A (2005) 1.91
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015) 1.91
Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci U S A (2005) 1.90
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression. Cancer Res (2005) 1.85
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem (2009) 1.81
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res (2007) 1.80
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res (2005) 1.76
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell (2010) 1.76
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced T cell leukemogenesis. Cancer Cell (2003) 1.71
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest (2008) 1.69
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid Redox Signal (2008) 1.66
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer (2003) 1.62
Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial. J Am Coll Cardiol (2012) 1.61
Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. Mol Cell Biol (2002) 1.59
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia. Blood (2011) 1.57
Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol (2002) 1.55
BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 1.55
Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol (2010) 1.54
Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res (2010) 1.52
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52
Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol (2005) 1.51
Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nat Protoc (2012) 1.51
Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg (2005) 1.50
An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res (2012) 1.49
Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci (2010) 1.48
Retracted Sp100 as a potent tumor suppressor: accelerated senescence and rapid malignant transformation of human fibroblasts through modulation of an embryonic stem cell program. Cancer Res (2010) 1.46
Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res (2010) 1.45
Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol (2014) 1.43
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Cleavage of MCM2 licensing protein fosters senescence in human keratinocytes. Cell Cycle (2008) 1.42
Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol (2007) 1.41
Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res (2011) 1.40
The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J Biol Chem (2002) 1.40
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A (2010) 1.37
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res (2007) 1.37